By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences today reported fourth-quarter revenues of $12.4 million, beating analysts' consensus estimate of $10.4 million.

The Menlo Park, Calif.-based sequencing technology firm said that it delivered and installed 17 instruments and had six bookings during the quarter ended Dec. 31. As of the end of the year, the company had a backlog of 16 PacBio RS instruments, which represent around $11 million in revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.